Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham(Ionis Pharmaceuticals (United States)), Rosanne M. Crooke(Ionis Pharmaceuticals (United States)), Charles P. Whipple(Ionis Pharmaceuticals (United States)), Kristina M. Lemonidis(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Stanley Foundation), Amuthakannan Subramaniam(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States))
Cited by 291
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k